Trucking company PACCAR (NASDAQ:PCAR) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 16% year on year to $6.91 billion. Its non-GAAP profit of $1.46 per share was 7.5% below analysts’ consensus estimates.
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the company’s full-year revenue guidance of $753 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0 per share was in line with analysts’ consensus estimates.
Packaged foods company Kraft Heinz (NASDAQ:KHC) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 6.4% year on year to $6.00 billion. Its non-GAAP profit of $0.62 per share was 2.7% above analysts’ consensus estimates.
Real estate services firm Cushman & Wakefield (NYSE:CWK) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 4.6% year on year to $2.28 billion. Its non-GAAP profit of $0.09 per share was significantly above analysts’ consensus estimates.
Automotive manufacturer General Motors (NYSE:GM) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 2.3% year on year to $44.02 billion. Its non-GAAP profit of $2.78 per share was 4.3% above analysts’ consensus estimates.
Environmental solutions provider CECO Environmental (NASDAQ:CECO) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 39.9% year on year to $176.7 million. The company’s full-year revenue guidance of $725 million at the midpoint came in 3.5% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was 17.6% above analysts’ consensus estimates.
Construction equipment company Astec (NASDAQ:ASTE) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 6.5% year on year to $329.4 million. Its non-GAAP profit of $0.88 per share was 91.3% above analysts’ consensus estimates.
Alternate site health provider Option Care Health (NASDAQ:OPCH) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 16.3% year on year to $1.33 billion. The company’s full-year revenue guidance of $5.5 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.40 per share was 19% above analysts’ consensus estimates.
Discover UNIVERSAL TECHNICAL INSTITUT, an undervalued growth gem. NYSE:UTI is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.
Water technology company Xylem (NYSE:XYL) announced better-than-expected revenue in Q1 CY2025, with sales up 1.8% year on year to $2.07 billion. The company expects the full year’s revenue to be around $8.75 billion, close to analysts’ estimates. Its non-GAAP profit of $1.03 per share was 8% above analysts’ consensus estimates.
POTUS warns of vetoing any bill that cuts Social Security or federal health programs. GOP's tax plan may target Medicaid, setting up a key 2026 debate.
Water heating and treatment solutions company A.O. Smith (NYSE:AOS) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 1.5% year on year to $963.9 million. The company’s full-year revenue guidance of $3.85 billion at the midpoint came in 0.5% above analysts’ estimates. Its GAAP profit of $0.95 per share was 5.4% above analysts’ consensus estimates.
